Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Oncologic Patients—A New Promise? Preliminary Results
Ron Batash, Noam Asna, Syed Ahsan Ali, Tatiana Charkovsky, Murad Asali, Sharon Pelles, Moshe Schaffer
Cancers October 15, 2025 DOI: 10.3390/cancers17203321 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Clinical trial Randomized Peer reviewed |
|---|---|
| Population | Patients with chemotherapy-induced peripheral neuropathy |
| Topics | Ketamine |
| Keywords | Amitriptyline Peripheral neuropathy Transdermal Randomized controlled trial Clinical trial Anesthesia Surgery Chemotherapy-related skin toxicity |
| Citations | 2 |
| Key findings | A topical combination of amitriptyline and ketamine at new concentrations appears safe and effective for symptomatic relief of CIPN. |
Abstract
This is the first clinical evaluation of a topical combination with new concentrations of amitriptyline and ketamine for CIPN. The results suggest this formulation offers a safe and effective option for symptomatic relief. Larger randomized controlled trials and exploration of transdermal delivery systems are warranted to validate these findings and optimize treatment outcomes.